Last updated on February 2018

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors


Brief description of study

This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.

Clinical Study Identifier: NCT03023319

Contact Investigators or Research Sites near you

Start Over

UCCI Clinical Trials Office

UC Health
Cincinnati, OH United States
  Connect »